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tality, 17.1%; p = 0.03). Regarding cumulative mortality, the 
AUC was 0.67 for the EuroScore II, 0.62 for the logistic Euro­
Score and 0.55 for the STS­PROM score for predicting mor­
tality at total follow­up. Conclusions: In this patient cohort, 
the EuroScore II performed best in predicting short­ and 
long­term mortality. Copyright © 2013 S. Karger AG, Basel
Introduction
Degenerative aortic stenosis (AS) is the most common 
valvular heart disease in Western communities and is 
continuously increasing in the aging population [1]. 
Without intervention, symptomatic AS has a poor out-
come with an average survival of less than 4 years [2]. 
Until recently, surgical aortic valve replacement (AVR) 
has been considered as standard treatment for such pa-
tients [2, 3]. However, for patients not referred to open-
heart surgery due to advanced age, severe comorbidities 
or an expected high operative mortality, transcatheter 
aortic valve implantation (TAVI) has become a less inva-
sive treatment alternative [2, 4–6].
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Abstract
Objectives: In the evaluation of patients considered for 
transcatheter aortic valve implantation (TAVI), the Euro­
Score II might be superior to established risk scores. Meth-
ods: We assessed the performance of the EuroScore II in pre­
dicting mortality in a cohort of 350 TAVI patients. Results: 
The EuroScore II and the logistic EuroScore were higher in 
nonsurvivors compared to survivors at 30 days (12.6 ± 1.8 
vs. 7.5 ± 0.3%, p < 0.001 for EuroScore II, and 27.7 ± 2.8 vs. 
22.1 ± 0.8%, p = 0.04 for logistic EuroScore), while the STS­
PROM score did not differ (7.3 ± 0.8 vs. 6.4 ± 0.3%, p = 0.09). 
The area under the curve (AUC) was 0.70 for the EuroScore 
II, 0.61 for the logistic EuroScore and 0.59 for the STS­PROM 
score for predicting 30­day mortality. Based on the estimat­
ed 30­day mortality risk, 3 risk groups were identified, a low­
risk (EuroScore II ≤4%, 30­day mortality 1.2%), an intermedi­
ate­risk (EuroScore II between 4% and 9%, 30­day mortality 
8.6%) and a high­risk group (EuroScore II >9%, 30­day mor­
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To predict morbidity and mortality after surgical pro-
cedures, different risk-scoring algorithms based on both 
patient history and functional status have been estab-
lished. The most widely applied risk-scoring systems are 
the logistic European System for Cardiac Operative Risk 
Evaluation (EuroScore) and the Society of Thoracic Sur-
geons Predicted Risk of Mortality (STS-PROM) score. A 
novel version of the EuroScore, the EuroScore II, has re-
cently been developed as the logistic EuroScore was 
known to overestimate mortality rates, in particular in 
high-risk patients [7–10]. In patients undergoing AVR, 
the STS score has been shown to better predict mortality 
compared to the logistic EuroScore [11, 12]. In addition 
to these well-established risk algorithms, several other 
risk-scoring systems such as the Cleveland Clinic Score 
or the Australian risk prediction model have been pro-
posed as risk models in patients with valvular or coronary 
heart disease [13–16].
In the era of TAVI, it is of particular importance to 
identify patients with severe AS at high surgical risk who 
may benefit from this treatment. Accordingly, different 
risk algorithms are commonly used in addition to a com-
prehensive clinical risk stratification of an individual pa-
tient. TAVI is currently recommended for high-risk or 
inoperable patients including those with surgical contra-
indications, severe comorbidities or increased surgical 
risk [17]. However, the reliability of the established risk 
algorithms in patients evaluated for TAVI has recently 
been questioned. The logistic EuroScore, the STS-PROM 
score and the EuroScore II have not been validated to spe-
cifically predict mortality after TAVI. Despite the wide 
use of these risk scores in the context of TAVI, there is 
little data on the performance of the revised EuroScore II 
in comparison to the established risk models, i.e. the lo-
gistic EuroScore and the STS-PROM score. Indeed, pre-
diction of mortality rates in patients evaluated for TAVI 
differs considerably among different scoring systems 
with conflicting results among different studies. In trans-
apically treated patients, the study by Haensig et al. [18] 
showed that the STS-PROM score was a better predictor 
of 30-day mortality than the new EuroScore II, while an-
other study did not confirm these results [19]. In the two 
most recent studies including both transapically and 
transfemorally treated patients, the EuroScore II tended 
to perform better with regard to discriminatory power 
compared to the logistic EuroScore and the STS-PROM 
score, in particular in the transfemorally treated patient 
cohort [20, 21].
The aim of this study was to further characterize the 
performance of the EuroScore II in comparison to the lo-
gistic EuroScore and the STS-PROM score in a larger 
TAVI population with regard to both early and late mor-
tality, and to delineate different EuroScore II risk catego-
ries (low risk, intermediate risk and high risk) with re-
spect to survival after TAVI.
Methods
Patients and Procedures
The present study included 350 patients with severe AS (mean 
transaortic systolic pressure gradient of ≥40 mm Hg, or an aortic 
valve area of <1.0 cm2 or <0.6 cm2/m2) undergoing TAVI at the 
University Hospital Zurich, Switzerland. All patients were evalu-
ated for TAVI by a multidisciplinary board of interventional car-
diologists, cardiac surgeons, cardiac anesthesiologists and imaging 
specialists (i.e. a ‘heart team’) [11]. In all patients, comprehensive 
clinical assessment, transthoracic and transesophageal echocar-
diography, coronary angiography and multislice computed to-
mography were performed before the procedure. The procedure 
was performed in the cardiac catheterization laboratory or the hy-
brid operation room. Procedural details have previously been re-
ported [22]. In 341 patients, the procedure was performed under 
general anesthesia, and in 9 patients it was done under local anes-
thesia. The Medtronic CoreValve (26, 29 and 31 mm), the Edwards 
SAPIEN (23, 26 and 29 mm), and the Medtronic Engager (26 mm) 
prostheses were utilized. 
All scores were calculated online using the official websites and 
calculators (logistic EuroScore: http://euroscore.org/calcold.html; 
EuroScore II: http://euroscore.org/calc.html; STS-PROM score: 
http://riskcalc.sts.org/STSWebRiskCalc273/de.aspx). The study 
was approved by the local ethical committee. Written informed 
consent was obtained from all patients.
Statistical Analysis
Continuous variables are presented as means ± standard er-
ror, or medians and interquartile range, as appropriate. Categor-
ical variables are given as frequencies and percentages. Prognos-
tic results are the numbers of events that occur over time. They 
were expressed: (1) in absolute terms (e.g. 30-day mortality rates), 
(2) in relative terms (e.g. risk from prognostic scores) and (3) in 
survival curves (cumulative events over time). Continuous vari-
ables were tested for differences with ANOVA or the Mann-
Whitney/Kruskal-Wallis test, as appropriate. Categorical vari-
ables were tested by Pearson’s χ2 test or Fisher’s exact test as ap-
propriate. Correlation analysis of different scores was performed 
using Spearman’s correlation coefficient. Discriminatory power 
was assessed by receiver-operation characteristic (ROC) curve 
evaluation and the area under the curve (AUC) accompanied by 
95% confidence intervals (CIs). Calibration, comparing the ob-
served and the predicted probabilities for equal-sized quantiles of 
risk, was evaluated by the Hosmer-Lemeshow goodness-of-fit 
test. Cut-off points were calculated using exhausted χ2 Automat-
ic Interaction Detection (exhausted CHAID), a type of decision 
tree technique, based upon adjusted significance testing (Bonfer-
roni testing). The Cox proportional hazards model was used to 
estimate the hazard ratio and CIs, respectively, to adjust for dif-
fering risk factor distributions between groups. A two-sided p 
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value of <0.05 was considered statistical significant. All statistical 
analyses were performed using IBM-SPSS version 20 (IBM Corp., 
Armonk, N.Y., USA) and R 2.15 for Windows.
Results
Patient Characteristics
Mean age was 82.2 ± 7.1 years. Sex was equally distrib-
uted (48.9% male). Transfemoral procedures were per-
formed in 83% (n = 289) of the patients and transapical 
procedures in 17% (n = 61), respectively. The CoreValve 
prosthesis was used in 65% (n = 189) of the patients, the 
Edwards SAPIEN prosthesis in 45% (n = 158) and the 
Medtronic Engager prosthesis in 1% (n = 3), respectively. 
Patients were at high surgical risk as expressed by a mean 
EuroScore II of 8.0 ± 0.3%, a mean logistic EuroScore of 
22.6 ± 0.7% and a mean STS-PROM score of 6.5 ± 0.3%. 
In patients treated with an Edwards SAPIEN prosthe-
sis, mean EuroScore II was 8.3 ± 0.6%, mean logistic 
 EuroScore 22.5 ± 1.1% and mean STS-PROM score 6.6 ± 
10.4%, respectively. In patients treated with a Medtronic 
CoreValve prosthesis, mean EuroScore II was 7.7 ± 0.4%, 
mean logistic EuroScore 22.7 ± 1.0% and mean STS-
PROM score 6.4 ± 0.4%. For all three scores, there were 
no significant differences between the two prosthesis 
types (p = 0.85 for logistic EuroScore, p = 0.87 for Euro-
Score II, and p = 0.80 for STS-PROM score, respectively).
Half of the patients (i.e. 49.7% or 174/350) had a logis-
tic EuroScore >20%, and 14.6% (51/350) a STS-PROM 
score >10%. The patient characteristics are summarized 
in table 1.
Predicted versus Observed Mortality at 30 Days
Thirty-day all-cause mortality was 9.1% without any 
significant difference between access sites (14.8% in 
transapically treated patients vs. 8.0% in transfemorally 
treated patients, p = 0.09) and prosthesis types (7.0% in 
patients treated with an Edwards SAPIEN prosthesis vs. 
10.5% in patients treated with a Medtronic CoreValve 
prosthesis, p = 0.18). 
Regarding risk score quartiles, the logistic EuroScore 
overestimated mortality, in particular in high-risk pa-
tients for whom mortality was overestimated by a factor 
3.3. The STS-PROM score underestimated mortality, in 
particular in low-risk patients for whom mortality was 
2.5 times higher than predicted (table 2). The EuroScore 
II and the logistic EuroScore were significantly higher in 
Table 1. Baseline characteristics
Baseline characteristics EuroScore II p value
<4% 4–9% >9%
Age, years 84.0 (79.6–64.0) 84.0 (81.0–88.0) 82.0 (78.0–85.3) 0.004
Male 54 (51) 60 (44) 57 (52) 0.42
Body mass index, kg/m2 24.9 (22.5–28.8) 26.5 (23.5–29.4) 26.0 (23.6–29.7) 0.13
Procedural characteristics
Edwards SAPIEN prosthesis 51 (49) 54 (40) 53 (48) 0.16
Transapical access 11 (11) 22 (16) 28 (26) 0.01
Personal history
Diabetes mellitus 17 (16) 29 (22) 37 (34) 0.008
Hypertension 73 (70) 102 (76) 91 (83) 0.08
Chronic obstructive pulmonary disease 18 (17) 24 (18) 27 (25) 0.30
Peripheral vascular disease 13 (12) 24 (18) 44 (40) <0.001
Cerebrovascular disease 13 (12) 31 (23) 36 (33) 0.002
Coronary artery disease 47 (45) 80 (59) 76 (69) 0.001
Renal failure (GFR <60 ml/min) 58 (55) 93 (69) 78 (71) 0.03
Reduced LVEF (<50%) 15 (14) 39 (29) 50 (46) <0.001
Symptoms
NYHA class III and IV 61 (58) 103 (76) 91 (83) <0.001
Results are presented as number and percentages or median and interquartile ranges. p ≤ 0.05 denotes a significant difference be-
tween patients of the different EuroScore II groups. GFR = Glomerular filtration rate; LVEF = left ventricular ejection fraction; NYHA = 
New York Heart Association.
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patients who died within the first 30 days after the proce-
dure compared to those who survived (12.6 ± 1.8 vs. 7.5 ± 
0.3%, p < 0.001 for the EuroScore II; fig. 1a; and 27.7 ± 2.8 
vs. 22.1 ± 0.8%, p = 0.04 for the logistic EuroScore; fig. 1b). 
The STS-PROM score did not differ between nonsurvi-
vors and survivors at 30 days (7.3 ± 0.8 vs. 6.4 ± 0.3%, p = 
0.09; fig. 1c). 
All-cause mortality at 30 days was 12.0% in the first 
half of patients, and 6.3% in the second half (p = 0.07), 
reflecting the learning curve of the operators. In patients 
treated with an Edwards SAPIEN prosthesis, all-cause 
mortality at 30 days was 9.1% in the first half and 4.9% in 
the second half of patients (p = 0.31), and in those treated 
with a Medtronic CoreValve prosthesis, it was 13.7% in 
the first and 7.4% in the second half (p = 0.16), respec-
tively. There was no significant difference with regard to 
30-day all-cause mortality between prosthesis types (p = 
0.35 in the first half, and p = 0.50 in the second half of pa-
tients, respectively).
Both logistic EuroScore as well as EuroScore II were 
significantly higher in the first half of patients compared 
Table 2. Risk quartiles of the EuroScore II, the logistic EuroScore 
and the STS-PROM score
Patients 
at risk
Observed 
mortality,
%
Predicted 
mortality,
%
EuroScore II
1st 85 1.2 2.23±0.08
2nd 91 8.8 4.62±0.08
3rd 87 10.3 8.07±0.13
4th 87 16.1 17.04±0.70
Log EuroScore
1st 87 4.6 8.89±0.30
2nd 88 9.1 15.89±0.24
3rd 88 10.2 24.05±0.29
4th 8 12.6 41.75±1.35
STS score
1st 89 6.7 2.74±0.06
2nd 87 6.9 4.20±0.04
3rd 90 8.9 5.86±0.08
4th 84 14.3 13.55±0.75
Fig. 1. Risk scores in survivors (S) and nonsurvivors (NS) after TAVI at 30 days (a–c) and at total follow-up (d–f). p ≤ 0.05 denotes a 
significant difference between survivors and nonsurvivors.
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to the second half (24.3 ± 1.1 vs. 21.0 ± 1.0, p = 0.009 for 
the logistic EuroScore, and 10.0 ± 0.6 vs. 6.0 ± 0.3 for the 
EuroScore II, p < 0.001), while, in contrast, the STS-
PROM score was lower in the first half of patients (5.7 ± 
0.3 vs. 7.3 ± 0.5, p = 0.02).
Patients with a reduced left ventricular ejection frac-
tion (LVEF) <35% had a higher observed 30-day mortal-
ity compared to those with a LVEF >35% (17.9 vs. 
7.7%, p = 0.03). In patients with a LVEF <35%, both the 
EuroScore II as well as the logistic EuroScore were higher 
compared to patients with a LVEF >35% (13.1 ± 1.5 vs. 
7.3 ± 0.3%, p < 0.001 for the EuroScore II, and 37.5 ± 2.8 
vs. 20.4 ± 0.7%, p < 0.001 for the logistic EuroScore, re-
spectively). The STS-PROM score did not differ signifi-
cantly between patients with a LVEF <35% and those with 
a LVEF >35% (7.2 ± 0.8 vs. 6.2 ± 0.3%, p = 0.29).
Risk Score Performance in Predicting 30-Day 
Mortality 
Spearman’s correlation coefficient revealed a moder-
ate correlation between the EuroScore II and the logistic 
EuroScore (r = 0.59, p < 0.001), while both the EuroScore 
II and the logistic EuroScore only weakly correlated with 
the STS-PROM score (r = 0.30, p < 0.001 for the Euro-
Score II, and r = 0.32, p < 0.001 for the logistic EuroScore, 
respectively).
ROC curve analysis showed that all three risk scores 
were suboptimal in predicting 30-day mortality (fig. 2). 
The EuroScore II had a better predictive value compared 
to the logistic EuroScore or the STS-PROM-Score. In 
ROC analysis, the AUC was 0.70 (95% CI 0.61–0.78, p < 
0.001) for the EuroScore II, 0.61 (95% CI 0.50–0.72, p = 
0.04) for the logistic EuroScore and 0.59 (95% CI 0.49–
0.69, p = 0.09) for the STS-PROM score for predicting 
30-day mortality. A cut-off value of 20% for the logistic 
EuroScore had a sensitivity of 0.63 and a specificity of 
0.52  in predicting 30-day mortality. A cut-off value of 
10% for the STS-PROM Score had a sensitivity of 0.22 and 
a specificity of 0.86 in predicting 30-day mortality. The 
Hosmer-Lemeshow test did not show any lack of calibra-
tion for all scores. Calibration by Hosmer-Lemeshow χ2 
was 10.3 (p = 0.15) for the EuroScore II, 12.1 (p = 0.25) 
for the logistic EuroScore and 2.6 (p = 0.96) for the STS-
PROM score, respectively.
Risk Score Performance in Predicting Cumulative 
Mortality
Mean follow-up was 410 ± 22 days. Regarding cumu-
lative mortality, the EuroScore II and the logistic Euro-
Score were significantly higher in patients who died 
compared to those who survived following TAVI (11.2 ± 
1.0 vs. 7.1 ± 0.3%, p < 0.001 for the EuroScore II; fig. 1d; 
and 27.1 ± 1.7 vs. 21.4 ± 0.8%, p = 0.001 for the logistic 
EuroScore; fig. 1e). Regarding cumulative mortality, the 
STS-PROM score did not differ between nonsurvivors 
and survivors (6.7 ± 0.5 vs. 6.5 ± 0.3%, p = 0.09; fig. 1f). 
In ROC analysis for predicting cumulative mortality, 
the AUC was 0.67 (95% CI 0.61–0.74, p < 0.001) for the 
EuroScore II, 0.62 (95% CI 0.55–0.69, p = 0.001) for the 
logistic EuroScore and 0.55 (95% CI 0.48–0.62, p = 0.19) 
for the STS-PROM score. 
Low-Risk, Intermediate-Risk and High-Risk TAVI 
Patients Based on EuroScore II Calculations
According to calculated optimal cut-off points for the 
EuroScore II, the patient cohort was divided into three 
groups: a low-risk group with a EuroScore II ≤4% and a 
30-day mortality rate of 1.2%, an intermediate-risk 
group with a EuroScore II between 4 and 9% and a 30-
day mortality rate of 8.6%, and a high-risk group with a 
EuroScore II >9% and a 30-day mortality rate of 17.1% 
(p = 0.03; fig. 3a). The Cox proportional hazards model 
Fig. 2. ROC curves for predicting 30-day mortality. ROC curve 
analysis showing the prognostic value of EuroScore II (green, AUC 
0.70), logistic EuroScore (blue, AUC 0.61) and STS-PROM score 
(orange, AUC 0.59). 
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was used to estimate the hazard ratio and CIs, respec-
tively, to adjust for differing risk factor distributions be-
tween groups (intermediate-risk group: HR 2.1, 95% CI 
0.99–4.44, p = 0.05 vs. low-risk group; high-risk group: 
HR 2.87, 95% CI 1.38–5.97, p = 0.005 vs. low-risk group; 
fig. 3b).
Discussion
This study demonstrates that in TAVI patients the 
EuroScore II outperformed the logistic EuroScore and 
the STS-PROM score with regard to discriminatory 
power in predicting all-cause mortality at 30 days as well 
as over the entire follow-up period. However, all three 
scores are not ideally suited to predict mortality in these 
patients. Nevertheless, based on estimated 30-day mor-
tality risk as calculated by the EuroScore II, three differ-
ent risk groups of mortality (low, intermediate and high 
risk, respectively) could be defined. 
Despite the fact it has been primarily designed for pa-
tients considered for major cardiac surgery, in particular 
coronary artery bypass grafting, the logistic EuroScore 
has been widely used in patients evaluated for AVR [23]. 
However, a progressive loss of calibration of the logistic 
EuroScore has been observed over time with expected 
and observed mortalities diverging as both patient risk 
profiles and operative mortalities changed since its intro-
duction in 1999 [23, 24]. It is well-known that in patients 
evaluated for AVR, the logistic EuroScore overestimates 
the risk of mortality, in particular in high-risk and in el-
derly patients [25]. Of note, these patients are potential 
candidates for transcatheter procedures (TAVI) in which 
optimal risk prediction for patient selection is particu-
larly important. Previous studies have demonstrated that 
the logistic EuroScore clearly overestimated mortality in 
TAVI patients, in particular in those at high risk [19, 25, 
26]. In line with these data, in our TAVI patient cohort, 
the logistic EuroScore clearly overestimated 30-day mor-
tality, in particular in patients at high risk by a factor of 
3.3. These findings are important since overestimation of 
the mortality risk might lead the heart team to select 
TAVI, although AVR would still have been feasible. Of 
note, current real-life registries demonstrate a general 
Fig. 3. Low-risk, intermediate-risk and high-risk TAVI patients 
calculated by EuroScore II. a According to calculated optimal cut-
off points for EuroScore II, the patient cohort was divided into 
three groups: a low-risk group with a EuroScore II ≤4% and a 30-
day mortality of 1.2%, an intermediate-risk group with a Euro-
Score II between 4 and 9% and a 30-day mortality of 8.6%, and a 
high-risk group with a EuroScore II >9% and a 30-day mortality of 
17.1%, respectively (p = 0.03). b The Cox proportional hazards 
model was used to estimate the hazard ratio and CIs to adjust for 
differing risk factor distributions between groups (intermediate-
risk group: HR 2.1, 95% CI 0.99–4.44, p = 0.05; high-risk group: 
HR 2.87, 95% CI 1.38–5.97, p = 0.005).
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trend towards lower risk patients selected for TAVI [27, 
28]; based on our results such patients might be at an even 
lower risk than suggested by currently used risk scores. 
More importantly, overestimation of procedural risk 
might shift potential TAVI candidates to medical man-
agement.
In contrast to the logistic EuroScore, the STS-PROM 
score underestimated the observed 30-day mortality of 
9.1%, predicting a 30-day mortality of 6.5%. In low-risk 
patients the mortality was 2.5 times higher than predict-
ed. Previous studies have reported similar findings after 
cardiac surgery [12]. Piazza et al. [29] compared the per-
formance of the logistic EuroScore to the STS score in 
TAVI patients. In line with observations in patients un-
dergoing AVR, the STS score also had a better predictive 
ability than the logistic EuroScore in TAVI patients [11, 
25, 29].
The EuroScore II was recently proposed as an updat-
ed version of the logistic EuroScore to improve risk pre-
diction after cardiac surgery [8, 10, 30]. Variables such 
as  poor mobility, NYHA functional class and diabetes 
were incorporated into the new risk model. Different cat-
egories of renal impairment, pulmonary hypertension 
and LVEF, as well as different grades of pulmonary hy-
pertension were included into the risk algorithm. Re-
duced mobility due to neurological dysfunction or to 
musculoskeletal dysfunction was also added. Despite 
these efforts, a multicenter validation study demonstrat-
ed that the EuroScore II did not improve the performance 
in the higher tertiles of risk in patients undergoing major 
cardiac surgery [8, 30]. Moreover, Chalmers et al. [31] 
recently demonstrated that the EuroScore II failed to im-
prove on the original logistic EuroScore model for iso-
lated AVR and miscellaneous procedures.
Comparing the three scores in TAVI patients in this 
patient cohort, the EuroScore II outperformed the two 
other scores in predicting 30-day mortality with an AUC 
of 0.70 compared to 0.61 for the logistic EuroScore and 
0.59 for the STS-PROM score, respectively. Moreover, 
both versions of the EuroScore were significantly differ-
ent between nonsurvivors and survivors at 30 days, while 
the STS-PROM score was not. In line with the usual learn-
ing curve for establishing new procedures, mortality 
tended to be lower in the second half of patients. Interest-
ingly, both versions of the EuroScore were lower in the 
second half of patients, while contradictory results were 
obtained for the STS-PROM score. Thus, the STS-PROM 
score in particular seems to address patient characteris-
tics less well in the TAVI population. Patients with a re-
duced LVEF are an important subgroup of patients in the 
population evaluated for TAVI, and this subgroup is 
known to have an increased risk of mortality after TAVI. 
Both versions of the EuroScore correctly identified the 
increased risk of mortality in patients with reduced LVEF, 
while the STS-PROM score predicted similar 30-day 
mortality rates for both patient groups. In line with our 
findings two studies recently compared the perfor-
mance of the EuroScore II in TAVI patients to the logistic 
EuroScore and the STS-PROM score with regard to short-
term mortality. In both studies, the EuroScore II tended 
to have a better discriminatory power in 30-day mortality 
risk prediction compared to the logistic EuroScore, in 
particular in transfemorally treated patients [20, 21].
Based on the current data from our TAVI patient co-
hort, a low-risk, intermediate-risk and high-risk patient 
group was defined utilizing the EuroScore II. Patients 
with EuroScores below 4% comprised the low-risk group 
(observed 30-day mortality of 1.2%), those with values 
between 4 and 9% the intermediate risk group (observed 
30-day mortality of 8.6%), and those with EuroScores 
above 9% the high-risk group (observed 30-day mortality 
of 17.1%), respectively. In addition to short-term out-
come prediction, a subdivision of patients within these 
three risk groups significantly differentiated cumulative 
survival after TAVI. The proposed stratification into dif-
ferent risk groups might help in part to anticipate expect-
ed procedural complications and postinterventional 
mortality in individual patients evaluated for TAVI. 
However, risk categories and cut-off values for the Euro-
Score II need to be evaluated prospectively in large TAVI 
patients cohorts and better refined to further improve the 
predictive discriminative power of this score, which still 
performs below expectations.
With regard to long-term mortality prediction, both 
the EuroScore and the STS-PROM score have been 
shown to predict mortality after cardiac surgery for up to 
14 years [32, 33]. Interestingly, the STS-PROM score per-
formed nearly as well in predicting long-term survival af-
ter cardiac surgery compared to 30-day mortality [33]. In 
our TAVI patient cohort, the EuroScore II outperformed 
the logistic EuroScore and the STS-PROM score with re-
gard to discriminatory power in the prediction of cumu-
lative mortality. Interestingly, the EuroScore II predicted 
long-term mortality almost as well as short-term mortal-
ity. To our knowledge, this is the first study comparing 
the EuroScore II to established scores in predicting long-
term outcome in TAVI patients. Hence, the EuroScore II 
can be used to estimate the likelihood not only of short-
term, but also of long-term survival. Besides the predic-
tion of short-term mortality, the ability to predict long-
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term outcome after TAVI is important, and will even be-
come more important with the aging of the population 
and the anticipated extension of transcatheter procedures 
to younger patients.
However, all currently available risk scores have sub-
stantial limitations. Predicted mortality varies consider-
ably depending on the risk score utilized as different vari-
ables with diverse weighting are incorporated. All scores 
were derived from cardiac databases of patients undergo-
ing cardiac surgery, mainly coronary artery bypass graft-
ing, and both age and risk profiles of patients undergoing 
cardiovascular procedures have changed considerably 
since the logistic EuroScore and the STS-PROM score 
were established [34]. With regard to TAVI, patients eval-
uated for transcatheter procedures are somewhat differ-
ent to those scheduled for heart surgery. Patients current-
ly undergoing TAVI are a highly selected group of high-
risk elderly patients with numerous comorbidities, and 
these risk characteristics were underrepresented in the 
patients in whom risk algorithms were established, and 
various additional variables such as liver disease, frailty, 
porcelain aorta, or previous radiotherapy are not includ-
ed in current risk models [29, 35, 36]. In line with previ-
ous studies, all three evaluated scores overall had subop-
timal discriminatory power and calibration in the TAVI 
patient population [29]. In our opinion, a risk-scoring 
system specifically developed for TAVI patients is imper-
ative as it has the potential to: (1) improve patient selec-
tion for transcatheter versus surgical procedures and (2) 
enhance short- and long-term outcome prediction after 
TAVI. However, it is of utmost importance to emphasize 
the need for clinical assessment of patients, preferably by 
a multidisciplinary heart team.
A limitations of this study is its single-center design. 
However, comprehensive clinical data was available in all 
patients treated with both the Edwards SAPIEN and the 
Medtronic CoreValve prosthesis. 
In conclusion, this study demonstrates that the Euro-
Score II is superior to both the logistic EuroScore and 
the STS-PROM score in predicting both short-term and 
cumulative long-term mortality in patients undergoing 
TAVI. Furthermore, this study emphasizes the specific 
need for a risk algorithm designed for TAVI patients, and 
the importance of a thorough clinical assessment which 
allows choice of an individualized strategy for each pa-
tient. 
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